Zaans Medisch Centrum Stichting

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Chronic lymphocytic leukaemia3 trials
• Heart failure2 trials
• Lung cancer2 trials
• Stroke2 trials
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Diffuse large B-cell lymphoma1 trial
• Mantle cell lymphoma1 trial
• Multiple myeloma1 trial
• Multiple sclerosis1 trial
• and 2 more

Phase

• Phase 312 trials
• Phase 22 trials
• Phase 41 trial

Status

• Recruiting6 trials
• Completed5 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting3 trials
• Amgen1 trial
• Amgen Inc.1 trial
• Amsterdam UMC1 trial
• Bayer AG1 trial
• and 8 more

Running trials

• Not yet recruiting

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· The Netherlands Cancer Institute· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

  NCT04909684· Phase 3· Stichting Radboud universitair medisch centrum· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Leiden University Medical Center· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

  2022-502664-21-00· Phase 4· Amsterdam UMC· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Genmab· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia2 recruiting
• Heart failure2 recruiting
• Colorectal cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN)

  2024-516581-11-00· Phase 3· Stichting Amsterdam UMC· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source